XML 75 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Segment Reporting Information [Line Items]    
Total revenues $ 12,982 $ 35,340
Cost of product revenue 4,521 8,521
Research and development 16,655 19,500
Selling, general and administrative 15,399 15,705
Restructuring charges 72 0
Total costs and operating expenses 36,647 43,726
Loss from operations (23,665) (8,386)
Unallocated depreciation and amortization (1,466) (1,215)
Stock-based compensation 2,809 3,838
Performance Enzymes    
Segment Reporting Information [Line Items]    
Total revenues 9,486 33,099
Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Total revenues 3,496 2,241
Operating Segments    
Segment Reporting Information [Line Items]    
Total revenues 12,982 35,340
Cost of product revenue 4,521 8,521
Research and development 15,411 18,468
Selling, general and administrative 3,749 4,261
Restructuring charges 72 0
Total costs and operating expenses 23,753 31,250
Loss from operations (10,771) 4,090
Operating Segments | Performance Enzymes    
Segment Reporting Information [Line Items]    
Total revenues 9,486 33,099
Cost of product revenue 4,521 8,521
Research and development 8,099 6,122
Selling, general and administrative 2,798 3,541
Restructuring charges 0 0
Total costs and operating expenses 15,418 18,184
Loss from operations (5,932) 14,915
Stock-based compensation 1,035 1,690
Operating Segments | Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Total revenues 3,496 2,241
Cost of product revenue 0 0
Research and development 7,312 12,346
Selling, general and administrative 951 720
Restructuring charges 72 0
Total costs and operating expenses 8,335 13,066
Loss from operations (4,839) (10,825)
Stock-based compensation 413 410
Corporate    
Segment Reporting Information [Line Items]    
Total costs and operating expenses (10,364) (11,205)
Unallocated depreciation and amortization (1,466) (1,232)
Loss before income taxes (22,601) (8,347)
Stock-based compensation 1,361 1,738
Product revenue    
Segment Reporting Information [Line Items]    
Total revenues 8,364 30,690
Product revenue | Performance Enzymes    
Segment Reporting Information [Line Items]    
Total revenues 8,364 30,690
Product revenue | Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Total revenues 0 0
Product revenue | Operating Segments    
Segment Reporting Information [Line Items]    
Total revenues 8,364 30,690
Product revenue | Operating Segments | Performance Enzymes    
Segment Reporting Information [Line Items]    
Total revenues 8,364 30,690
Product revenue | Operating Segments | Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Total revenues 0 0
Research and development revenue    
Segment Reporting Information [Line Items]    
Total revenues 4,618 4,650
Research and development revenue | Performance Enzymes    
Segment Reporting Information [Line Items]    
Total revenues 1,122 2,409
Research and development revenue | Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Total revenues 3,496 2,241
Research and development revenue | Operating Segments    
Segment Reporting Information [Line Items]    
Total revenues 4,618 4,650
Research and development revenue | Operating Segments | Performance Enzymes    
Segment Reporting Information [Line Items]    
Total revenues 1,122 2,409
Research and development revenue | Operating Segments | Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Total revenues $ 3,496 $ 2,241